Agilent Technologies Appoints Ron Nersesian President and COO
News Nov 15, 2012
Nersesian has been executive vice president and chief operating officer since November 2011.
Nersesian, 53, will continue to be responsible for Agilent's Chemical Analysis (CAG), Life Sciences (LSG), Electronic Measurement (EMG), and Agilent Order Fulfillment (AOF) businesses, with the presidents of those groups reporting to him. Nersesian will continue to report to William (Bill) Sullivan, who remains chief executive officer.
Nersesian first joined Hewlett-Packard Co., Agilent's predecessor company, in 1984. Since then he has served in various management positions, including president of the electronic measurement business from 2009 to 2011.
Nersesian holds a bachelor's degree in electrical engineering from Lehigh University and an MBA from New York University, Stern School of Business.
"Ron is an outstanding global business leader," said Sullivan. "He transformed EMG when he headed that business, resulting in record profitable growth across current and emerging markets."
"Over the past year as COO, Ron made significant strides in increasing the profitability of our life science and chemical analysis businesses even as we navigated through a difficult economy," said Sullivan.
Sullivan added, "Ron's appointment as president and COO is an opportunity for Agilent to further leverage the skills of an executive with an exceptional record of business growth, cost improvements and superior return on invested capital."
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Agilent Technologies Presents Thought Leader Award to Dr. Ram SasisekharanNews
Agilent Technologies awards Dr. Ram Sasisekharan with the Agilent Thought Leader Award in recognition of his contributions in the field of biologics characterization.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Comments | 0 ADD COMMENT
Like what you just read? You can find similar content on the communities below.Analysis & Separations Cell Science Diagnostics Drug Discovery Genomics Research Informatics & Automation
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for FreeLOGIN SUBSCRIBE FOR FREE
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018